Literature DB >> 19965779

Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/- mouse: magnetic resonance imaging assessment.

Alan R Olzinski1, Gregory H Turner, Roberta E Bernard, Heather Karr, Carla A Cornejo, Karpagam Aravindhan, Bao Hoang, Michael A Ringenberg, Pu Qin, Krista B Goodman, Robert N Willette, Colin H Macphee, Beat M Jucker, Clark A Sehon, Peter J Gough.   

Abstract

UNLABELLED: Purpose- This study assessed the pharmacological effect of a novel selective C-C chemokine receptor (CCR) 2 antagonist (GSK1344386B) on monocyte/macrophage infiltration into atherosclerotic plaque using magnetic resonance imaging (MRI) in an atherosclerotic mouse model. METHODS AND
RESULTS: Apolipoprotein E(-/-) mice expressing human CCR2 were fed a Western diet (vehicle group) or a Western diet plus10 mg/kg per day of GSK1344386B (GSK1344386B group). After the baseline MRI, mice were implanted with osmotic pumps containing angiotensin II, 1000 ng/kg per minute, to accelerate lesion formation. After five weeks of angiotensin II administration, mice received ultrasmall superparamagnetic iron oxide, an MRI contrast agent for the assessment of monocyte/macrophage infiltration to the plaque, and underwent imaging. After imaging, mice were euthanized, and the heart and aorta were harvested for ex vivo MRI and histopathological examination. After 5 weeks of dietary dosing, there were no significant differences between groups in body or liver weight or plasma cholesterol concentrations. An in vivo MRI reflected a decrease in ultrasmall superparamagnetic iron oxide contrast agent uptake in the aortic arch of the GSK1344386B group (P<0.05). An ex vivo MRI of the aortic root also reflected decreased ultrasmall superparamagnetic iron oxide uptake in the GSK1344386B group and was verified by absolute iron analysis (P<0.05). Although there was no difference in aortic root lesion area between groups, there was a 30% reduction in macrophage area observed in the GSK1344386B group (P<0.05).
CONCLUSIONS: An MRI was used to noninvasively assess the decreased macrophage content in the atherosclerotic plaque after selective CCR2 inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965779     DOI: 10.1161/ATVBAHA.109.198812

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  Monocyte chemoattractant protein-1 deficiency protects against visceral fat-induced atherosclerosis.

Authors:  Miina K Ohman; Andrew P Wright; Kevin J Wickenheiser; Wei Luo; Hana M Russo; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-18       Impact factor: 8.311

2.  Distinct functions of CXCR4, CCR2, and CX3CR1 direct dendritic cell precursors from the bone marrow to the lung.

Authors:  Hideki Nakano; Miranda R Lyons-Cohen; Gregory S Whitehead; Keiko Nakano; Donald N Cook
Journal:  J Leukoc Biol       Date:  2017-02-01       Impact factor: 4.962

Review 3.  The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.

Authors:  Angela Pirillo; Fabrizia Bonacina; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  Curr Atheroscler Rep       Date:  2018-02-14       Impact factor: 5.113

Review 4.  PET imaging of aortic atherosclerosis: Is combined imaging of plaque anatomy and function an amaranthine quest or conceivable reality?

Authors:  Gary R Small; Terrence D Ruddy
Journal:  J Nucl Cardiol       Date:  2011-08       Impact factor: 5.952

Review 5.  Regulation of atherogenesis by chemokines and chemokine receptors.

Authors:  Wuzhou Wan; Philip M Murphy
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-07       Impact factor: 4.291

6.  Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression.

Authors:  Yasunori Iida; Baohui Xu; Haojun Xuan; Keith J Glover; Hiroki Tanaka; Xiaolei Hu; Naoki Fujimura; Wei Wang; Joshua R Schultz; Court R Turner; Ronald L Dalman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

7.  Molecular imaging of macrophage enzyme activity in cardiac inflammation.

Authors:  Muhammad Ali; Benjamin Pulli; John W Chen
Journal:  Curr Cardiovasc Imaging Rep       Date:  2014-04-01

8.  CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

Authors:  Timothy Sullivan; Zhenhua Miao; Daniel J Dairaghi; Antoni Krasinski; Yu Wang; Bin N Zhao; Trageen Baumgart; Linda S Ertl; Andrew Pennell; Lisa Seitz; Jay Powers; Ruiping Zhao; Solomon Ungashe; Zheng Wei; Landin Boring; Chia-Lin Tsou; Israel Charo; Robert D Berahovich; Thomas J Schall; Juan C Jaen
Journal:  Am J Physiol Renal Physiol       Date:  2013-08-28

9.  Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.

Authors:  Michelle L D'Antoni; Brooks I Mitchell; Sara McCurdy; Mary Margaret Byron; Debra Ogata-Arakaki; Dominic Chow; Nehal N Mehta; William A Boisvert; Eric Lefebvre; Cecilia M Shikuma; Lishomwa C Ndhlovu; Yvonne Baumer
Journal:  J Leukoc Biol       Date:  2018-08-08       Impact factor: 4.962

10.  Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade.

Authors:  Gemma E White; Eileen McNeill; Ivy Christou; Keith M Channon; David R Greaves
Journal:  Mol Pharmacol       Date:  2011-05-17       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.